<DOC>
	<DOCNO>NCT00804141</DOCNO>
	<brief_summary>This one-year study evaluate long-term safety tolerability subcutaneous ( skin ) injection form MOA-728 treatment opioid-induced constipation subject nonmalignant pain . The study consist 2 week screening period , 48 week open-label treatment period 2 week follow-up period . Subjects need agree self-administer subcutaneous injection , complete daily diary , check-in via daily telephone call year-long period .</brief_summary>
	<brief_title>Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>men woman 18 year old , history pain least 2 month duration study entry due document underlying nonmalignant condition , history constipation due opioid use nonmalignant condition , diagnosis significant GI disorder bowel obstruction , fecal incontinence rectal prolapse example , history active inflammatory bowel disease , irritable bowel syndrome , megacolon within 6 month study entry , history malignancy chronic constipation initiation opioid therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>treatment opioid-induced constipation</keyword>
</DOC>